Fasidotril Eli Lilly

Current Opinion in Investigational Drugs

Volumn 4, Issue 9, 2003, Pages 1113-1119

  Ozdener, Fatih ^a   Ozdemir, Vural ^b  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENKEPHALINASE INHIBITOR; FASIDOTRIL; FASIDOTRILAT; GLYCOPRIL; ICATIBANT; LOSARTAN; MEMBRANE METALLOENDOPEPTIDASE; OMAPATRILAT; PLACEBO; PRODRUG; PROTEINASE INHIBITOR; RAMIPRIL; THIORPHAN; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BLOOD PRESSURE MEASUREMENT; CHEMICAL MODIFICATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DISEASE SEVERITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG INDICATION; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TOXICITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; EUROPE; FLUSHING; GENETIC POLYMORPHISM; GLUCOSE METABOLISM; HEADACHE; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEMODYNAMIC MONITORING; HUMAN; HYPERTENSION; INSOMNIA; INSULIN SENSITIVITY; LEG DISEASE; LEG EDEMA; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PHARMACOGENOMICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; UNITED STATES;

ALANINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION, RENOVASCULAR; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0142245364     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. 158246 New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: Rational design, bioavailability, and pharmacological responses in experimental hypertension. Fournie-Zaluski MC, Coric P, Turcaud S, Rousselet N, Gonzalez W, Barbe B, Pham I, Jullian N, Michel JB, Roques BP J Med Chem 1994 37 8 1070-1083 This paper discusses structure-activity considerations for rational design of dual ACE/NEP inhibitors.
2. 200976 Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): Rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Gros C, Noel N, Souque A, Schwartz JC, Danvy D, Plaquevent JC, Duhamel L, Duhamel P, Lecomte JM, Bralet J Proc Natl Acad Sci USA 1991 88 10 4210-4214 An original and significant report on rational design of fasidotril considering the structural characteristic of the catalytic sites for ACE and NEP. The study also includes critical data on in vitro inhibition constants of fasidotril for ACE and NEP enzymes.
3. 253771 Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene. Wegner M, Hirth Dietrich C, Knorr A, Dressel J, Ganten D, Stasch JP Hypertens Res 1996 19 3 151-159
4. 267506 Systemic and regional hemodynamic effects of a new angiotensin converting enzyme and neutral endopeptidase mixed inhibitor, alatriopril, in the dog. Richard V, Lecomte JM, Thuillez C Arch Mal Coeur Vaiss 1993 86 8 1275-1279
5. 293376 Acute natriuretic effect of fasidotrilat, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in rats with heart failure. Marie C, Mossiat C, Lecomte JM, Bralet J Pharmacology 1998 56 6 291-296
6. 302316 Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction. Marie C, Mossiat C, Lecomte JM, Schwartz JC, Bralet J J Pharmacol Exp Ther 1995 275 3 1324-1331
7. 325242 Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction. Marie C, Mossiat C, Gros C, Schwartz JC, Lecomte JM, Bralet J Cardiovasc Res 1999 41 3 544-553
8. 327979 Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA J Pharmacol Exp Ther 1998 287 2 567-577
9. 359022 Protease inhibitors: Current status and future prospects. Leung D, Abbenante G, Fairlie DP J Med Chem 2000 43 3 305-341
10. 406376 Vasopeptidase inhibition as a new concept in antihypertensive therapy. Dendorfer A, Dominiak P Kidney Blood Pressure Research 2000 23 3-5 178-179
11. 424860 Omapatrilat (Bristol-Myers Squibb). Tabrizchi R Curr Opin Investig Drugs 2001 2 10 1414-1422 This paper provides and in-depth overview of the clinical pharmacology of omapatrillat, a model vasopeptidase inhibitor.
12. 426705 Lilly and Bioproject collaborate on novel class of compounds for hypertension and congestive heart failure. Eli Lilly & Co Press Release 2001 October 24
13. 426786 Lilly outlines its strategy to become the pharmaceutical growth company of the decade. Eli Lilly & Co Press Release 2001 October 24
14. 429413 Lilly fasidotril hypertension filing expected by 2006: CHF two years later. FDC Reports Pink Sheet 2001 63 45 28
15. 438424 A review of vasopeptidase inhibitors: A new modality in the treatment of hypertension and chronic heart failure. Nathisuwan S, Talbert RL Pharmacotherapy 2002 22 1 27-42
16. 438425 Novel angiotensin II inhibitors in cardiovascular medicine. Burnier M Expert Opin Investig Drugs 2001 10 11 1957-1964
17. 475365 Vasopeptidase inhibitors: A new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics. Molinaro G, Rouleau JL, Adam A Curr Opin Pharmacol 2002 2 2 131-141
18. 475368 Vasopeptidase inhibitors. Weber MA Lancet 2001 358 9292 1525-1532
19. 475370 Vasopeptidase inhibitors: An emerging class of cardiovascular drugs. Bralet J, Schwartz JC Trends Pharmacol Sci 201 22 3 106-109
20. 475373 Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Laurent S, Boutouyrie P, Azizi M, Marie C, Gros C, Schwartz JC, Lecomte JM, Bralet J J Hypertension 2000 35 5 1148-1153
21. 475374 Fasidotril: The first dual inhibitor of neprilysin and ACE. Bralet J, Marie C, Gros C, Schwartz JC, Lecomte JM Cardiovasc Drug Rev 2000 18 1 1-24
22. 475368 Vasopeptidase inhibitors. Weber MA Lancet 2001 358 9292 1525-1532
23. 496833 Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. Mukae S, Itoh S, Aoki S, Iwata T, Nishio K, Sato R, Katagiri T J Hum Hypertens 2001 16 12 857-863 This paper describes a pharmacogenomic study that illustrates the clinical utility of genetic biomarkers for a priori identification of patients at risk for drug toxicity.
24. 496845 Revisiting salt and water retention: New diuretics, aquaretics, and natriuretics. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr Med Clin North Am 2003 87 2 475-491
25. 496847 The therapeutic effect of natriuretic peptides in heart failure; Differential regulation of endothelial and inducible nitric oxide synthases. Calderone A Heart Failure Rev 2003 8 1 55-70
26. 496853 Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in rat. Kubota E, Dean RG, Hubner RA, Casley DJ, Johnston CI, Burrell LM Clin Sci 2003 105 3 339-345 This paper describes an ex vivo characterization of the effects of omapatrilat, a model vasopeptidase inhibitor, on ACE and NEP in various tissue in rat. The results indicate that the degree of ACE and NEP inhibition differs from tissue to tissue, suggesting, by extension, that the side-effect profile of vasopeptidase inhibitors may be determined in part at the end-organ level.
27. 496857 Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. Wang CH, Leung N, Lapointe N, Szeto L, Uffelman KD, Giacca A, Rouleau JL, Lewis GF Circulation 2003 107 14 1923-1929
28. 496859 Vasopeptidase inhibition: A novel approach to cardiovascular therapy. Floras JS Can J Cardiol 2002 18 2 177-182
29. 496860 Vasopeptidase inhibition: A double-edged sword? Campbell DJ Hypertension 2003 41 3 383-389 A thoughtful review highlighting the potential shortcomings of vasopeptidase inhibitors and the complex interplay between natriuretic peptide hormonal systems and the neutral endopeptidase.
30. 496863 Pharmacogenomics of drugs affecting the cardiovascular system. Siest G, Ferrari L, Accaoui MJ, Batt AM, Visvikis S Clin Chem Lab Med 2003 41 4 590-599 An overview of the role of genetic variation in drug metabolism and drug targets as it applies to cardiovascular agents.
31. 496866 Exon 1 polymorphism of the B2BKR gene does not influence the clinical status of patients with hereditary angioedema. Freiberger T, Vyskocilova M, Kolarova L, Kuklinek P, Krystufkova O, Lahodna M, Hanzlikova J, Litzman J Hum Immunol 2002 63 6 492-494
32. 500048 Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat. Heudi O, Ramirez Molina C, Marshall P, Amour P, Amour A, Peace S, McKeown S, Abou Shakra F J Peptide Science 2002 8 11 591-600
33. 50052 What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? Ozdemir V, Shear NH, Kalow W Drug Saf 2001 24 2 75-85
34. 500060 Comparison of omapatrilat and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K Circulation 2002 106 8 920-926
35. 500063 Omapatrilat - The story of OVERTURE and OCTAVE. Coats AJ Int J Cardiol 2002 86 1 1-4
36. 500064 Recent clinical trials with omapatrilat: New developments. Zanchi A, Maillard M, Burnier M Curr Hypertension Reports 2003 5 4 346-352
37. 500651 Lilly: EPS prep pack, 2Q 2003. Grofik G, Assenza M Citigroup Smith Barney 2003 July 22
38. 500656 Industry update: Large-cap pharma 2003 2Q03 earning preview. Goldstein M, Suvannavejh G, McRea K CIBC World Markets Inc (Canada) 2003 July 14
39. 500659 Lilly (Eli) & Co. Rissinger D, Boris J, Li B, Calone J Merrill Lynch & Co 2003 June 12